Sarah Cannon Research Institute Joins the Caris Precision Oncology Alliance

News
Article

Organizations aim to advance precision oncology and biomarker-driven research.

Male doctor is consulting with a young man about prostate cancer and venereal disease and sexual dysfunction about the causes of erectile dysfunction in an examination room. Image Credit: Adobe Stock Images/Ratirath

Image Credit: Adobe Stock Images/Ratirath

Caris Life Sciences, an artificial intelligence (AI) TechBio company, announced that Sarah Cannon Research Institute (SCRI), an oncology research organization, has officially joined the Caris Precision Oncology Alliance (POA). According to Caris, the POA is a network of cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients.

"SCRI and Caris share a commitment to advancing therapies and expanding access to molecular diagnostic approaches for patients in the community," said Andrew McKenzie, PhD, VP, personalized medicine, SCRI; scientific director, Genospace. "We are pleased to join the Caris Precision Oncology Alliance and look forward to the opportunities to leverage comprehensive genomic data to inform clinical development strategies to improve outcomes for people facing cancer."

Reference: The Caris Precision Oncology Alliance Welcomes Sarah Cannon Research Institute. PR Newswire. October 26, 2023. Accessed October 27, 2023. https://www.prnewswire.com/news-releases/the-caris-precision-oncology-alliance-welcomes-sarah-cannon-research-institute-301968199.html

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.